
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc is demonstrating a positive financial outlook with an upward revision of its FY26 EPS estimate to $(4.17) from a previous $(8.63) due to an increased share count. The anticipated approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud software platform and expected FDA approval of its first diagnostic algorithm in early 2026, positions the company for a significant market opportunity. These developments underline HeartSciences's commitment to enhancing cardiac screening technology and improving healthcare delivery in various clinical settings.
Bears say
HeartSciences Inc. faces significant risks that could negatively impact its stock outlook, including balance sheet and liquidity challenges, as well as uncertainties surrounding the safety and efficacy of its product candidates during clinical trials. The company's revised revenue estimate for FY2026 has been drastically lowered to $0.1 million from a previous projection of $1.2 million, primarily due to delays related to FDA approvals. Additionally, the firm must navigate competitive pressures, reimbursement challenges, and shifting macroeconomic and healthcare priorities, which further exacerbate the uncertainty surrounding its financial viability and market potential.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares